SCHEMBL2174168

SCHEMBL2174168

CCOC(=O)c1csc(C(C)N)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.61
NPC1 O15118 7/20 0.61
MAPT P10636 6/20 0.61
ALDH1A1 P00352 2/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
ABCB1 P08183 2/20 0.53
CYP1A2 P05177 2/20 0.52
CYP2C19 P33261 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.50
GAA P10253 3/20 0.50
POLB P06746 1/20 0.49
PKM P14618 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
HSP90AA1 P07900 3/20 0.47
TDP1 Q9NUW8 1/20 0.45
PTPRB P23467 1/20 0.44
MAPK1 P28482 1/20 0.44
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2440072 0.88 RAB9A (0.60) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL12548274 0.86 RAB9A (0.59) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL12902789 0.85 RAB9A (0.57) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL1246665 0.83 RAB9A (0.59) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL15111192 0.83 RAB9A (0.59) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL10042788 0.83 RAB9A (0.52) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL1059446 0.82 RAB9A (0.57) RAB9ANPC1MAPTALDH1A1MEN1
Hydrochloric Acid SCHEMBL20529546 0.82 RAB9A (0.54) RAB9ANPC1MAPTALDH1A1MEN1
Hydrochloric Acid SCHEMBL20529544 0.82 RAB9A (0.54) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL4835852 0.81 ABCB1 (0.56) RAB9ANPC1MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
EP-1730128-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-12-13 EP disclosed
WO-2005097765-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 RAB9A 2862/4885NPC1 1296/4885MAPT 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.